Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck/Ridgeback’s Lagevrio Could Get Another Chance As Others Face Limitations

New Analysis Shows No COVID-19 At Days 3 Or 5

Executive Summary

New data for molnupiravir could mean new commercial life for Merck and Ridgeback’s oral COVID-19 therapy, which had fallen behind due to the outstanding efficacy for Pfizer’s Paxlovid.

You may also be interested in...



ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill

Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.

US Restricts Use of GSK/Vir’s Xevudy, Deemed ‘Unlikely’ To Help Against Rising Omicron Variant

The constantly mutating SARS-CoV-2 has evaded yet another antibody therapy, but Vir and GSK hope that a higher dose of Xevudy could retain some efficacy against BA.2. 

Merck’s Molnupiravir And The Meaning Of ‘Access’

COVID pill’s EUA fact sheet includes the politically potent term ‘accessible,’ and the question of availability could be among the most important for the product – unless more clinical data turns it into a winner in its own right.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC146163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel